2020
DOI: 10.21626/vestnik/2020-2/06
|View full text |Cite
|
Sign up to set email alerts
|

Correction of functional disorders in ADMA-like preeclampsia with derivatives of the peptide imitating erythropoietin α-helix B

Abstract: Objective. The aim of the study is to investigate the correction of functional disorders in ADMA-like preeclampsia with derivatives of the peptide imitating erythropoietin α-helix B. Materials and methods. The study was performed in 120 white female Wistar rats weighing 250-300 g. ADMA-like preeclampsia was used as experimental preeclampsia. To assess the effectiveness of the pharmacological agents used, blood pressure, microcirculation in the placenta, and proteinuria were recorded, the content of final NO m… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
2

Relationship

1
1

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 3 publications
0
1
0
Order By: Relevance
“…Erythropoietin short-chain derivatives, the classic example of which is pHBPS, are most promising in this regard (Brines et al 2015;Xiong et al 2015;Korokin et al 2020a). The possibility to give them additional properties by modifying the polypeptide chain, in particular, the antiplatelet activity with the cytoprotective activity remaining at the same level, is of major importance (Golubev et al 2020b;Gureev et al 2020;Korokin et al 2020b;Puchenkova et al 2020). For the study, we selected a polypeptide EP-11-1 (UEHLERALNSS), which has antiplatelet and cytoprotective activities (Antsiferov et al 2020;Korokin et al 2020c;Korokin et al 2021).…”
Section: Introductionmentioning
confidence: 99%
“…Erythropoietin short-chain derivatives, the classic example of which is pHBPS, are most promising in this regard (Brines et al 2015;Xiong et al 2015;Korokin et al 2020a). The possibility to give them additional properties by modifying the polypeptide chain, in particular, the antiplatelet activity with the cytoprotective activity remaining at the same level, is of major importance (Golubev et al 2020b;Gureev et al 2020;Korokin et al 2020b;Puchenkova et al 2020). For the study, we selected a polypeptide EP-11-1 (UEHLERALNSS), which has antiplatelet and cytoprotective activities (Antsiferov et al 2020;Korokin et al 2020c;Korokin et al 2021).…”
Section: Introductionmentioning
confidence: 99%